Hisashi Okuda
Papers
1
Total Citations
2
H-Index
1
About
Hisashi Okuda is a clinical researcher whose work focuses on the intersection of immunotherapy and radiotherapy for advanced urological malignancies, particularly bladder cancer. His most cited paper, "Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer With Rectal Metastases" (2023), addresses a critical gap in treating rare, aggressive metastatic presentations. Okuda’s major contribution lies in demonstrating that combining immune checkpoint inhibition with targeted radiation can achieve durable responses where conventional chemotherapy (gemcitabine/cisplatin) and radical surgery have historically failed—a finding that challenges treatment paradigms for oligometastatic urothelial carcinoma. While his citation count is currently modest (2 citations), the work is notable for its clinical novelty and potential to improve outcomes in a patient population with no established standard of care. Okuda’s research underscores a growing trend toward personalized, multimodal strategies in genitourinary oncology, offering hope for long-term survival in cases previously deemed incurable. His future work may further validate this synergistic approach across other metastatic sites.
Research Focus
Key Achievements
Top Papers
- 1